Clinical Data’s FAMILION^® Family of Tests to be Highlighted by Two Presentations at Heart Rhythm 2008

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its portfolio of proprietary genetic biomarkers, announced today that its PGxHeatlh™ division will feature two presentations at the Heart Rhythm Society’s Heart Rhythm 2008 conference. The presentations are on Long QT Syndrome, an inherited cardiac condition for which the company offers a proprietary test.

“PGxHealth’s continued participation in gatherings of this nature highlights our commitment to work with academicians and leading healthcare providers to disseminate vital information related to our tests,” said Carol Reed, MD, Executive Vice President and Chief Medical Officer of Clinical Data. “Having the test information aggregated in a manner that leads to ongoing enhancements to the science underlying the test increases its value for physicians, patients, and their families. Heart Rhythm 2008 is a critical gathering of key heart disease decision makers, and we are proud to bring such compelling data to this audience year-after-year.”

Clinical Data’s PGxHealth division provides tests for heart diseases that include Long QT Syndrome, Brugada Syndrome and CPVT. Additionally, a family testing option exists for each of these conditions. The FAMILION tests are built on the company’s already significant and growing portfolio of intellectual property rights, domain knowledge and relationships with leading innovators.

During HRS, PGxHealth and its academic colleagues will give two presentations on Long QT syndrome. In the first, an abstract entitled “Distinguishing Long QT Syndrome-Causing Mutations from ‘Background’ Genetic Noise,” researchers will examine how to identify informative factors for determining the likelihood of pathogenicity for rare, non-synonymous mutations.

A second abstract by the same authors titled “Amino Acid Physicochemical Differences May Serve as an Adjunct to Frequency Analysis to Determine Mutation Pathogenicity in Long QT Syndrome,” will scrutinize whether physicochemical properties would further discriminate between case mutations and control variants.

For more information about FAMILION please visit: www.pgxhealth.com/genetictests/familion.

About FAMILION^®

The FAMILION family of tests detects genetic mutations that can cause cardiac channelopathies. Cardiac channelopathies are rare, potentially lethal heart conditions, including Long QT Syndrome (LQTS), Brugada Syndrome (BrS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

By detecting genetic mutations, the FAMILION tests can be used to recognize inherited forms of cardiac channelopathies in individuals and their families, helping to guide treatment and helping to reduce the deadly cardiac events they can cause.

For cardiac channelopathies that have already been diagnosed, the test can help doctors and patients make more informed treatment decisions and aid in uncovering other possibly asymptomatic family members that may be at risk.

About Clinical Data, Inc.

Clinical Data, Inc. is unlocking the potential of molecular discovery from Targeted Science to Better Healthcare™. Its PGxHealth™ division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics™ division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the Company’s website at www.clda.com for more information.

About PGxHealth

PGxHealth has extensive experience and capabilities in the development, clinical validation and delivery of genomics-based tests, in particular of efficacy and safety biomarkers for appropriate drug utilization.

Through its own know-how and resources, work conducted with some of the world’s most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers Therapeutic Diagnostics™. Visit the company’s website at www.pgxhealth.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully introduce our new pharmacogenetic and molecular diagnostics products and services; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our PGxPredict™ pharmacogenomics tests will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Annual Report on Form 10-K for the fiscal year ended March 31, 2007, our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2007 and our Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.